Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | F13A1 | P00488 | 3/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octanedioate SCHEMBL4025944 | 1.00 | TSHR (0.44) | TSHRLMNANFKB1PMP22PTGS1 | |
| Propionic Acid SCHEMBL22749330 | 0.81 | FFAR3 (0.40) | KMT2AALDH1A1 | |
| SCHEMBL36368 | 0.79 | PARL (0.43) | — | |
| SCHEMBL28063863 | 0.78 | TSHR (0.38) | TSHRLMNANFKB1PMP22PTGS1 | |
| Octanedioate SCHEMBL7080168 | 0.78 | TSHR (0.55) | TSHRLMNANFKB1PMP22PTGS1 | |
| SCHEMBL29748565 | 0.77 | PARL (0.46) | LMNA | |
| SCHEMBL1841389 | 0.77 | LMNA (0.36) | TSHRLMNANFKB1PMP22PTGS1 | |
| Tetraxetan SCHEMBL3797845 | 0.76 | HSD17B10 (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| Octanedioate SCHEMBL6037661 | 0.76 | TSHR (0.52) | TSHRLMNANFKB1PMP22PTGS1 | |
| Azelaic Acid SCHEMBL28918234 | 0.76 | TSHR (0.52) | TSHRLMNANFKB1PMP22PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551565-B2 | CD44 targeted multi-arm conjugate | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| EP-3928797-B1 | CD44 TARGETED MULTI-ARM CONJUGATE | BRIGHTGENE BIO MEDICAL TECH CO LTD (CN) | 2024-10-09 | — | — | EP | disclosed |
| US-20220096644-A1 | CD44 TARGETED MULTI-ARM CONJUGATE | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2022-03-31 | — | — | US | disclosed |
| EP-0951480-A4 | METHOD AND NOVEL COMPOUNDS FOR USE THEREIN | BIOTA SCIENT MANAGEMENT (AU) | 2004-07-28 | — | — | EP | disclosed |
| US-6680054-B1 | SIALIC ACID DERIVATIVE FUNCTIONALIZED VIA 7-POSITION; INFLUENZA ANTIVIRAL AGENT | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2004-01-20 | — | — | US | disclosed |
| EP-0951480-A1 | METHOD AND NOVEL COMPOUNDS FOR USE THEREIN | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 1999-10-27 | — | — | EP | disclosed |
| WO-1998021243-A1 | METHOD AND NOVEL COMPOUNDS FOR USE THEREIN | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551565-B2 | CD44 targeted multi-arm conjugate | CD44, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MUC1 | TSHR 76/4885LMNA 2340/4885NFKB1 3020/4885 |
| US-20220096644-A1 | CD44 TARGETED MULTI-ARM CONJUGATE | CD44, BCL6, SIGLEC7 | TSHR 1040/4885LMNA 2401/4885NFKB1 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.